Equibles does not estimate personal net worth.
Get an email with a short summary when Palvella Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get PVLA alertsMatthew Korenberg is recorded as CFO at Palvella Therapeutics, Inc. (PVLA) since December 13, 2024. Palvella Therapeutics, Inc. reported in an 8-K filed December 16, 2024 that Matthew Korenberg was appointed Chief Financial Officer, effective December 13, 2024. Matthew Korenberg has spoken on 2 earnings calls across 1 company, most recently for Palvella Therapeutics, Inc. on August 4, 2026. Palvella Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Palvella Therapeutics, Inc. includes Wesley H. Kaupinen (CEO and Board Member), George M. Jenkins (Chairman and Board Member), James Geraghty (Chairman) and 7 others.
“In connection with the Merger and pursuant to the Merger Agreement, at the Effective Time, the following individuals were appointed to serve as executive officers and directors of the Company: Matthew Korenberg | 49 | Chief Financial Officer”
“As of June 30, 2026, Pelvella had approximately $251 million in cash, providing a significant financial flexibility to invest in maximizing the potential launch of the company's first commercial product, if approved.”
“Starting with the financials, Pelvela ended Q1 with $261.9 million in cash and cash equivalents, including our short-term investments in U.S. treasuries.”
2024-12-13–present
Biotechnology · Healthcare
CFO
2024-12-13–present
